322 related articles for article (PubMed ID: 8385618)
1. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
Papa SM; Engber TM; Boldry RC; Chase TN
Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata.
Ozer H; Ekinci AC; Starr MS
Brain Res; 1997 Nov; 777(1-2):51-9. PubMed ID: 9449412
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats.
Ouagazzal A; Nieoullon A; Amalric M
Psychopharmacology (Berl); 1993; 111(4):427-34. PubMed ID: 7870984
[TBL] [Abstract][Full Text] [Related]
4. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice.
Lapin IP; Rogawski MA
Behav Brain Res; 1995 Oct; 70(2):145-51. PubMed ID: 8561905
[TBL] [Abstract][Full Text] [Related]
5. Roles of NMDA and dopamine D1 and D2 receptors in the acquisition and expression of flavor preferences conditioned by oral glucose in rats.
Dela Cruz JA; Coke T; Icaza-Cukali D; Khalifa N; Bodnar RJ
Neurobiol Learn Mem; 2014 Oct; 114():223-30. PubMed ID: 25065714
[TBL] [Abstract][Full Text] [Related]
6. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride.
Martin P; Waters N; Waters S; Carlsson A; Carlsson ML
Eur J Pharmacol; 1997 Sep; 335(2-3):107-16. PubMed ID: 9369362
[TBL] [Abstract][Full Text] [Related]
7. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
Verma A; Kulkarni SK
Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866
[TBL] [Abstract][Full Text] [Related]
8. Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.
Engber TM; Anderson JJ; Boldry RC; Papa SM; Kuo S; Chase TN
Neuroscience; 1994 Mar; 59(2):389-99. PubMed ID: 8008198
[TBL] [Abstract][Full Text] [Related]
9. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
Moore NA; Blackman A; Awere S; Leander JD
Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
[TBL] [Abstract][Full Text] [Related]
10. Impairments of movement initiation and execution induced by a blockade of dopamine D1 or D2 receptors are reversed by a blockade of N-methyl-D-aspartate receptors.
Hauber W
Neuroscience; 1996 Jul; 73(1):121-30. PubMed ID: 8783236
[TBL] [Abstract][Full Text] [Related]
11. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists.
Anderson JJ; Kask AM; Chase TN
Eur J Pharmacol; 1996 Jan; 295(2-3):163-8. PubMed ID: 8720580
[TBL] [Abstract][Full Text] [Related]
12. N-methyl-D-aspartate receptor blockade impairs behavioural performance of rats in a reaction time task: new evidence for glutamatergic-dopaminergic interactions in the striatum.
Baunez C; Nieoullon A; Amalric M
Neuroscience; 1994 Aug; 61(3):521-31. PubMed ID: 7969928
[TBL] [Abstract][Full Text] [Related]
13. Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.
Parashos SA; Marin C; Chase TN
Neurosci Lett; 1989 Oct; 105(1-2):169-73. PubMed ID: 2485878
[TBL] [Abstract][Full Text] [Related]
14. Role of NMDA, opioid and dopamine D1 and D2 receptor signaling in the acquisition of a quinine-conditioned flavor avoidance in rats.
Rotella FM; Badalia A; Duenas SM; Hossain M; Saeed S; Touzani K; Sclafani A; Bodnar RJ
Physiol Behav; 2014 Apr; 128():133-40. PubMed ID: 24508751
[TBL] [Abstract][Full Text] [Related]
15. Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine.
Zheng P; Zhang XX; Bunney BS; Shi WX
Neuroscience; 1999; 91(2):527-35. PubMed ID: 10366010
[TBL] [Abstract][Full Text] [Related]
16. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
17. Microcatalepsy and disruption of forelimb usage during operant behavior: differences between dopamine D1 (SCH-23390) and D2 (raclopride) antagonists.
Fowler SC; Liou JR
Psychopharmacology (Berl); 1994 Jun; 115(1-2):24-30. PubMed ID: 7862901
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
Lublin H; Gerlach J; Peacock L
Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
[TBL] [Abstract][Full Text] [Related]
19. Different effects of dopamine antagonists on spontaneous and NMDA-induced motor activity in mice.
Giménez-Llort L; Martínez E; Ferré S
Pharmacol Biochem Behav; 1997 Mar; 56(3):549-53. PubMed ID: 9077595
[TBL] [Abstract][Full Text] [Related]
20. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
